Home/Temple OrthoBiologics/Samuel Ogunsalu

SO

Samuel Ogunsalu

Co-Founder & VP Product & Corporate Development

Temple OrthoBiologics

Therapeutic Areas

Orthopedics Sports Medicine

Temple OrthoBiologics Pipeline

Drug	Indication	Phase
TX-33	Prevention of scar tissue formation (arthrofibrosis) after joint injury or surgery	Pre-clinical

Leadership Team at Temple OrthoBiologics

Co-Founder & CEO

Riley J Williams III, MD

Co-Founder, Orthopedic Surgeon-Sports Medicine

Jens Thies, PhD. MBI

Co-Founder & Chief Scientific Officer

View full Temple OrthoBiologics profile